VERU - Veru Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.33
-0.03 (-2.56%)
As of 1:47PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.37
Open1.38
Bid1.33 x 1000
Ask1.36 x 900
Day's Range1.33 - 1.38
52 Week Range0.90 - 2.37
Volume19,621
Avg. Volume123,600
Market Cap82.31M
Beta (3Y Monthly)-0.10
PE Ratio (TTM)N/A
EPS (TTM)-0.40
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2014-04-28
1y Target Est7.38
Trade prices are not sourced from all markets
  • GlobeNewswire18 days ago

    First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy

    Veru Inc. (VERU), an oncology and urology biopharmaceutical company, today announced the enrollment of the first patient in its Phase 2 study of zuclomiphene citrate for the treatment of hot flashes caused by androgen deprivation therapy (ADT) for men with advanced prostate cancer. The double-blind, placebo-controlled, dose-finding study is designed to evaluate the safety and efficacy of daily oral zuclomiphene citrate in patients with moderate to severe hot flashes caused by ADT for advanced prostate cancer. The primary endpoint of the study is the mean change in frequency and severity of hot flashes relative to baseline at week 4.

  • GlobeNewswire22 days ago

    Veru to Present at Upcoming Healthcare Investor Conferences in New York

    MIAMI, Sept. 27, 2018-- Veru Inc., an oncology and urology biopharmaceutical company, today announced that the company’ s Chairman, President and Chief Executive Officer, Dr. Mitchell Steiner, will present ...

  • GlobeNewswire22 days ago

    Veru Announces Pricing of Public Offering of Common Stock

    Veru Inc. (VERU), an oncology and urology biopharmaceutical company, today announced the pricing of an underwritten public offering of 7,142,857 shares of its common stock at a price of $1.40 per share, for gross proceeds of $10 million, before deducting underwriting discounts and commissions and other estimated offering expenses.  In addition, Veru has granted the underwriters a 30-day option to purchase up to 1,071,428 additional shares of common stock at the public offering price, less underwriting discounts and commissions.  The offering is expected to close on or about October 1, 2018, subject to the satisfaction of customary closing conditions. Cantor Fitzgerald & Co. is acting as the sole book-running manager.  Oppenheimer & Co. Inc. is acting as lead manager and CIM Securities, LLC is acting as co-manager.  Ladenburg Thalmann & Co. Inc. acted as financial advisor to Veru.

  • GlobeNewswire23 days ago

    Veru Announces Proposed Public Offering of Common Stock

    Veru Inc. (VERU), an oncology and urology biopharmaceutical company,  today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the offering will be offered by Veru.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Veru intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. Cantor Fitzgerald & Co. is acting as the sole book-running manager. Oppenheimer & Co. Inc. is acting as lead manager.

  • GlobeNewswirelast month

    Veru has Successful Pre-IND Meeting with FDA for VERU-111 Next Generation Novel Oral Anti-Tubulin Therapy for Metastatic Prostate Cancer

    Veru Inc. (VERU), an oncology and urology biopharmaceutical company, announced today that it has completed a Pre-Investigational New Drug Application (pre-IND) meeting for VERU-111 in which the Food and Drug Administration (FDA) agreed with Veru’s plans for a Phase 1/2 clinical trial and that an IND may be submitted for the indication of men who have metastatic castration resistant prostate cancer and who have also become resistant to, or who have failed to respond to, ZYTIGA® (abiraterone) or XTANDI® (enzalutamide). In the preclinical toxicology studies which comprise the IND package, there was no observed neutropenia or myelosuppression.

  • GlobeNewswire2 months ago

    Veru to Ring NASDAQ Closing Bell on August 31 to Kick Off National Prostate Cancer Awareness Month

    Veru Inc. (VERU), a urology and oncology biopharmaceutical company, today announced that that it has been invited by NASDAQ to ring the closing bell on August 31, 2018, to kick off National Prostate Cancer Awareness Month. Veru Chief Corporate Officer Harry Fisch, M.D., will be joined by company management and other guests at the closing bell ceremony.

  • GlobeNewswire2 months ago

    Veru Announces Additional Information Regarding its South Africa Female Condom Tender Award

    MIAMI, Aug. 29, 2018-- Veru Inc., a urology and oncology biopharmaceutical company, today announced additional information regarding its recent award of 75% of a 120 million-unit South Africa female condom ...

  • GlobeNewswire2 months ago

    South Africa Female Condom Tender Award Additional Information

    Veru Inc. (VERU), a urology and oncology biopharmaceutical company, today announced additional information regarding its recent award of 75% of a 120 million-unit South Africa female condom tender. Veru also announced today that Dr. Steiner will present an overview of the company’s development programs at the H.C. Wainwright Global Investment Conference at 10:50 a.m. EDT on Sept. 6, 2018, at The St. Regis New York hotel.

  • GlobeNewswire2 months ago

    Veru Awarded 75 Percent of South Africa Female Condom Tender

    MIAMI, Aug. 27, 2018 (GLOBE NEWSWIRE) --  Veru Inc. (VERU), an oncology and urology biopharmaceutical company, today announced that its global public sector division, The Female Health Company, has been awarded 75 percent of a South Africa female condom tender. The overall tender is for up to 120 million female condoms in total and orders may be placed under the award during the next three years. “We are pleased to have received this significant award representing 75 percent of the total tender in South Africa,” said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru.

  • GlobeNewswire2 months ago

    Veru Reports Fiscal 2018 Third Quarter Financial Results

    --Investigational New Drug Application with the FDA Accepted for Phase 2 Study of Zuclomiphene--. --VERU-111 Preclinical Efficacy Data in Four Different Cancers Presented at American Society of Clinical ...

  • ACCESSWIRE2 months ago

    Veru Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Veru Inc (NASDAQ: VERU ) will be discussing their earnings results in their Q3 Earnings Call to be held on August 14, 2018 at 8:00 AM Eastern Time. To listen ...

  • GlobeNewswire2 months ago

    Veru to Report Fiscal 2018 Third-Quarter Financial Results, Host Conference Call on August 14th

    Veru Inc. (VERU), an oncology and urology biopharmaceutical company, today announced that on August 14, 2018, the company will report financial results for its fiscal 2018 third quarter that ended June 30, 2018, before the market opens.  Veru management will host a conference call that same day at 8 a.m. ET to review the company’s performance and answer questions. Interested investors may access the call by dialing 800-341-1602 from the U.S. or 412-902-6706 from outside the U.S. and asking to be joined into the Veru Inc. call. In addition, investors may access a replay of the conference call the same day beginning at approximately noon ET by dialing 877-344-7529 for US callers, or 412-317-0088 from outside the U.S., passcode 10122133.  The replay will be available for one week, after which, the recording will be available via the company’s website at https://verupharma.com/investors.

  • ACCESSWIRE8 months ago

    Veru Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 14, 2018 / Veru Inc. (NASDAQ: VERU ) will be discussing their earnings results in their Q1 Earnings Call to be held on February 14, 2018 at 8:00 AM Eastern Time. To ...